The program allows patients to undergo genetic testing and high-resolution retinal imaging anonymously and provide insights ...

In addition to Prevent Blindness’s usual free resources, the organization is providing a dedicated webpage, fact sheets, and ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

Patients express mixed feelings about AI in health care, favoring its use for documentation and administrative tasks while ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.

PYC Therapeutics advances VP-001 for retinitis pigmentosa, gaining FDA insights for its upcoming registrational trial.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

Perfuse Therapeutics is conducting trials for the treatment for glaucoma and diabetic retinopathy, aiming to restore vision ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care ...